Navigation Links
CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer

Clinic to Serve as rEEG(R) 'Center of Excellence' Advancing Performance in

Patient Outcomes, Costs and Convenience

COSTA MESA, Calif., Jan. 15 /PRNewswire-FirstCall/ -- CNS Response, Inc. (OTC Bulletin Board: CNSO) announced today that it has completed the previously announced acquisition of Neuro-Therapy Clinic, P.C., a neuropsychiatric clinic in Denver, Colorado. The Company also announced that Daniel A. Hoffman, MD has been appointed Chief Medical Officer. Dr. Hoffman, a neuropsychiatrist with more than 25 years experience, was previously National Medical Director of Neuro-Therapy Clinic.

Len Brandt, Chairman and CEO of CNS Response, reported, "Our close relationship with Dr. Hoffman and the Neurotherapy Clinic has already played a significant role in establishing the value of rEEG(R) guidance in medication management."

George Carpenter, President of CNS Response, commenting on the future, said, "We expect Neuro-Therapy Clinic to further define the opportunity to use technology in general, and rEEG in particular, to vastly improve clinic performance in patient outcomes, costs, and convenience and to best communicate this to all -- patient, physician, payer. In this way, the Neuro-Therapy Clinic is something of a dynamic laboratory discovering how to integrate technology and be a true center of excellence on all of these measures. Put to practice, this knowledge presents CNS Response with an opportunity to further our relationship with other clinics and physicians using rEEG."

"Dr. Hoffman is a leader and a true partner in the development of rEEG so we are particularly pleased to have him join our team," Mr. Brandt continued. "Dr. Hoffman will play a critical role in implementing our strategy for the validation and commercialization of our core rEEG platform."

Established in 1993, Neuro-Therapy Clinic, P.C. is a center for highly-advanced testing and treatment of neuropsychiatric problems, including learning, attentional and behavioral challenges, mild head injuries, as well as depression, anxiety, bipolar and all other common psychiatric disorders.

Dr. Hoffman served as Medical Director for Neuro-Therapy Clinic from 1993-2007. He also served as National Medical Director for CNS Response from 2004-2007 and has maintained a private practice in neuropsychiatry since 1977. He served as an Assistant Clinical Professor at the University of Colorado from 1977 to 1996.

Dr. Hoffman has lectured extensively throughout the country on leading-edge testing and treatment for Psychiatric Medication Selection and other brain related topics and has been published in more than 30 peer-reviewed articles. He is on the editorial boards of the Journal of Neurotherapy, the Journal of Applied Psychophysiology and Self Regulation and the Journal of Neuropsychiatry and Clinical Neurosciences.

About CNS Response

CNS Response is a life-sciences data company focused on the commercialization of the first patented commercial system that guides psychiatrists and other physicians to determine proper treatments for patients with behavioral (mental or addictive) disorders. This technology allows CNS Response to create and provide simple reports ("rEEG(R) Reports") that specifically guide physicians to treatment strategies based on the patient's own physiology.

rEEG(R) utilizes traditional electroencephalography (EEG) in conjunction with a normative database and a proprietary clinical (symptomatic) database to identify the following: (1) medication classes most likely to be needed; and (2) medications within these classes with the most probable treatment potential for each patient. Reports are provided to physicians in a relationship analogous to that of a reference laboratory. Prospective, retrospective and field studies of treatment-resistant patients have reported treatment success of 70% or greater in managed care, outpatient psychiatric and residential substance abuse clinical settings.

In addition to providing analytical support to physicians, CNS Response is also an aide to pharmaceutical developers, who can use rEEG to (1) stratify study populations to improve the success of FDA clinical trials; (2) provide insight on effective therapeutic dosing of investigational drugs; (3) identify additional indications for psychiatric medications; (4) provide insight into effective drug combinations; and (5) discover opportunities for decision analytics and support. In addition to these applications, CNS Response continues to investigate the use of rEEG analysis for development of proprietary pharmaceutical opportunities.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.


Investor Relations:

Sara Ephraim

(646) 536-7002


Jason Rando / Jennifer Saunders

(646) 536-7033 / 7011

SOURCE CNS Response, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CNS Response, Inc. Announces Acquisition of Neuropsychiatric Clinic
2. Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology
3. China Medical Technologies Completes Acquisition of BBE
4. Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses
5. Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program
6. Pharmos Corporation Completes Initial Closing of Private Placement
7. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
8. Edwards Lifesciences Completes Acquisition of CardioVations Product Line
9. Fovea Pharmaceuticals Completes EUR30M Series B Financing
10. Fundamental Applied Biology, Inc. Completes $21 Million Series B Financing
11. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
Post Your Comments:
(Date:10/8/2015)... Oct. 8, 2015 Celemics, a global pioneer ... the North American market with the establishment of Celemics ... and Europe , has secured itself ... Enrichment methodology and sample preparation for DNA sequencing and ... hereditary and somatic genetic testing more accurately, quickly, and ...
(Date:10/8/2015)... , Oct. 8, 2015  The ALS Association, in ... Assistive Technology Challenge to revolutionize communication technology solutions for ... --> ALS (amyotrophic lateral sclerosis) is a ... the brain and the spinal cord. Eventually, people with ... movement, which often leads to total paralysis and death ...
(Date:10/8/2015)... TORONTO, CANADA (PRWEB) , ... October 08, 2015 ... ... it has entered into an exclusive license agreement to develop and commercialize intellectual ... expands upon the original agreement from February 2009, and affords exclusive worldwide rights ...
(Date:10/7/2015)... (PRWEB) , ... October 07, 2015 , ... ... ( ) will present a public educational seminar on the latest advances ... October 10th from 1:00 pm – 3:00 pm at the Hilton Dallas/Southlake Town ...
Breaking Biology Technology:
... was at a security conference and stayed at a hotel, ... claimed that they had implemented it so only those on ... ,I do not purchase wireless Internet service when Im at ... the seminar hosts office. Out of curiosity, on my second ...
... Commerce has announced that it is producing the Wisconsin ... Thursday, September 25, from 8:30 a.m. to 3:45 p.m. ... , ,Wisconsins medical device and technology cluster is ... state, said Department of Commerce (Commerce) Secretary Cory L. ...
... all things e-commerce will speak to cutting-edge Madisonians Thursday evening ... Club Majestic, 115 King Street in downtown Madison. , ,Nationally ... about how e-commerce is coming out of the weeds after ... Some companies are finally learning how to please consumers and ...
Cached Biology Technology:
(Date:9/10/2015)... LONDON , Sept. 10, 2015 Report ... thus far not quite delivered upon previous expectations of ... might be the breakthrough year in which wearables begin ... been expected. One of the main reasons is the ... disrupt not only the SmartWatches market, but the overall ...
(Date:9/8/2015)... , Sept. 8, 2015   TREW Marketing ... new survey, Smart Marketing for Engineers TM : ... engineering professionals reveals insightful findings about engineers, preferences for ... of content engineers most value and trust, and where ... Marketers targeting technical audiences grapple with how to best ...
(Date:9/2/2015)... Biometric technology ... system which uses identical human characteristic such as ... and finger print. Increasing number of terror attacks ... which provides high level of security. Traditional security ... are vulnerable to attacks. Furthermore, Biometric technology uses ...
Breaking Biology News(10 mins):
... adults living closer to a fast food restaurant had a ... away from fast food, according to researchers at The University ... particularly strong among those with a lower income. ... of Public Health indicates higher BMI associates with residential ...
... relationship between the heritable risk for schizophrenia and low ... associated with cognitive impairments that may cause functional disability. ... to the risk for developing schizophrenia. For example, reduced ... Also, these deficits may be present in healthy relatives ...
... hematopoiesis at sites outside the bone marrow in ... (LMU) in Munich now show that a specific type ... blood cells. Balanced hematopoiesis is essential for the ... takes place mainly in the liver and the spleen. ...
Cached Biology News:
Sheep polyclonal to Melatonin ( Abpromise for all tested applications). Antigen: Melatonin Tg conjugate....
Goat polyclonal to DDDDK tag (FITC) ( Abpromise for all tested applications)....
Biology Products: